Want to see SE:STIL full AI Analyst Report?
STIL Stock Chart & Stats
kr186.50
-kr9.00(-3.81%)
At close: 4:00 PM EST
kr186.50
-kr9.00(-3.81%)
Day’s Range― - ―
52-Week Rangekr143.00 - kr283.00
Previous CloseN/A
Volume3.08K
Average Volume (3M)6.57K
Market Cap
kr2.05B
Enterprise Valuekr2.18K
Total Cash (Recent Filing)kr149.36M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)28.2
Beta0.25
Next Earnings
Oct 23, 2026EPS Estimate
1.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.09
Shares Outstanding8,985,447
10 Day Avg. Volume9,615
30 Day Avg. Volume6,571
Financial Highlights & Ratios
PEG Ratio-7.85
Price to Book (P/B)2.48
Price to Sales (P/S)3.10
P/FCF Ratio113.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.89
Revenue Forecast (FY)kr709.65M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt, equity-heavy balance sheet materially lowers financial distress risk and provides durable optionality. It supports long-term R&D, product development, targeted capex or acquisitions without refinancing risk, and cushions the business through cyclic healthcare spending cycles.
Healthy Gross And Net MarginsSustained high gross margins indicate strong product-level pricing power and specialized manufacturing advantages. Combined with positive net margins, this profitability profile supports reinvestment, margin resilience versus peers, and the ability to absorb modest cost swings over a multi‑quarter horizon.
Improving Scale And Revenue TrendEvidence of improved scale since 2023 signals the company is converting scale into better profitability. For a niche med‑tech instrument maker, durable revenue growth and scale advantages strengthen margins, distribution leverage, and product development ROI over the next several quarters.
Bears Say
Uneven Cash GenerationIntermittent FCF swings reduce dependable internal funding for capex, inventory, or commercial expansion. Over a 2–6 month horizon, this variability can constrain timing of investments, limit flexibility in price or contract negotiations, and heighten reliance on operational execution to sustain growth.
Moderate Capital EfficiencyROE in the high single digits suggests the sizeable equity base isn't being deployed at top-tier returns. Over time, modest capital efficiency can cap shareholder returns and indicate opportunities to better monetize assets or improve working capital, which may limit long‑term value creation.
Operating Cash Flow Modest Vs RevenueModest operating cash flow relative to revenue implies lower conversion of sales into durable free cash. This weakens the firm's ability to self-fund growth initiatives or weather extended investment cycles, increasing sensitivity to margin pressures and timing of receivables or inventory changes.
STIL FAQ
What was Stille AB’s price range in the past 12 months?
Stille AB lowest stock price was kr143.00 and its highest was kr283.00 in the past 12 months.
What is Stille AB’s market cap?
Stille AB’s market cap is kr2.05B.
When is Stille AB’s upcoming earnings report date?
Stille AB’s upcoming earnings report date is Oct 23, 2026 which is in 78 days.
How were Stille AB’s earnings last quarter?
Stille AB released its earnings results on Jul 23, 2026. The company reported kr2.29 earnings per share for the quarter, missing the consensus estimate of kr2.564 by -kr0.274.
Is Stille AB overvalued?
According to Wall Street analysts Stille AB’s price is currently Overvalued.
Does Stille AB pay dividends?
Stille AB pays a Annually dividend of kr1.8 which represents an annual dividend yield of N/A. See more information on Stille AB dividends here
What is Stille AB’s EPS estimate?
Stille AB’s EPS estimate is 1.84.
How many shares outstanding does Stille AB have?
Stille AB has 8,985,447 shares outstanding.
What happened to Stille AB’s price movement after its last earnings report?
Stille AB reported an EPS of kr2.29 in its last earnings report, missing expectations of kr2.564. Following the earnings report the stock price went down -1.538%.
Which hedge fund is a major shareholder of Stille AB?
Currently, no hedge funds are holding shares in SE:STIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Stille AB
Stille AB develops, manufactures, and distributes medtech products in Sweden and internationally. It operates through the Surgical Instruments and Surgical Tables segments. The Surgical Instruments segment offers surgical scissors, including SuperCut, eye, blepharoplasty, operating, vascular, tenotomy, and face-lift scissors; colon, gall duct, multi-purpose, tangential occlusion, peripheral vascular, and anastomosis clamps; skin and nerve hooks, retractors, rib spreaders, self-retaining and trachea retractors, and nasal specula; and dressing, diathermy, knot-holding, tissue, iris, dura, and vascular forceps under the STILLE, Fehling, and S&T brands. Its Surgical Tables segment provides C-arm tables, which are surgical tables used in ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular procedures under the imagiQ and MedStone brands. The company also offers instrument care education, repair and maintenance, and inspection services. Stille AB was founded in 1841 and is headquartered in Torshälla, Sweden.